11/12/2025
Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating
HONG KONG, December 11, 2025 - (ACN Newswire) – Since 2025, driven by both policy tailwinds and fundamental strengths, the innovative drug sector in the Hong Kong stock market has experienced a valuation recovery. Although it experienced some correction in the second half due to external environmental factors, its overarching growth logic remains intact. Institutional analysis indicates that innovative drugs continue to represent the clearest industry trend within the pharmaceutical sector, with promising development prospects ahead.
Read more: https://www.acnnewswire.com/press-release/english/104157/
Follow us for more updates.
Since 2025, driven by both policy tailwinds and fundamental strengths, the innovative drug sector in the Hong Kong stock market has experienced a valuation recovery.